Resources

22
Oct

App Note – Toxicity services for pharma, biotech and medical devices developers

Download this application note and discover 3 case studies. Refine formulations or assess local tolerance in human skin before clinical trials.

25
Sep

ADCC Argenx poster

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm the
Read more
16
Sep

Genoskin raises series A to advance human-based drug development

Genoskin raises $8.7M series Ato support drug development with ethical, human-based modelsFunding to accelerate global expansion and strengthen scientific leadership We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhance
Read more
10
Sep

WHITE PAPER – HypoSkin® & immunogenicity testing

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

26
Aug

Webinar #12 – Drug-specific antibody repertoires from allergics: a source of therapeutics?

Top-level science through the eyes of an expert.Join us for the next session of Naked Immunology Webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. In this session we will discuss how the immune system’s reaction to neuromuscular blockers could offer new therapeutic insights. WATCH NOWThis webinar explores new insights into the antibody responses of patients
Read more
20
May

APPLICATION NOTE – NativeSkin® & Pharma

NativeSkin® & PharmaApplication NoteNativeSkin®: a human skin model for pharma applications Discover NativeSkin®, an advanced ex vivo human skin model designed to provide a physiologically relevant, cruelty-free platform for pharmaceutical research. This patented model preserves the structure, cellular complexity, and barrier function of real human skin, enabling reliable assessments of drug efficacy (e.g., transdermal delivery, topical activity, anti-inflammatory effects) and
Read more